Clincosm LogoSign in Get a demo

LAMIPA: Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

Sponsor
Centre Hospitalier Régional Metz-Thionville (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05309018
Collaborator
(none)
35
Enrollment
5.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team.

This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.

Condition or Disease Intervention/Treatment Phase
  • Other: Interviews

Study Design

Study Type:
Observational
Anticipated Enrollment :
35 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients Followed for AML Treated With Oral Targeted Therapy
Anticipated Study Start Date :
Sep 15, 2022
Anticipated Primary Completion Date :
Oct 15, 2022
Anticipated Study Completion Date :
Mar 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients

Other: Interviews
Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.
medical staff

Other: Interviews
Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.

Outcome Measures

Primary Outcome Measures

  1. Perception of patient [Within 1 month]

    Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to patient.

Secondary Outcome Measures

  1. Perception of care team [Within 1 month]

    Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to care team.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Patient with AML

  • Treated with a new targeted oral therapy as monotherapy or in combination:

  • Venetoclax* in combination with ivosidenib (IDH1 inhibitor)

  • Onureg* (azacitin: pyrimidine analogue)

  • Venetoclax (BCL-2 protein inhibitor) in combination with subcutaneous azacitin

  • Whose follow-up is provided alternately by a hematologist and an IPA.

  • Affiliated to a social security scheme

Exclusion Criteria:

  • Moderate or severe cognitive impairment

  • Language barrier

  • Other communication disorders

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Centre Hospitalier Régional Metz-Thionville

Investigators

  • Principal Investigator: Jennifer HUET, CHR Metz Thionville Hopital de Mercy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Régional Metz-Thionville
ClinicalTrials.gov Identifier:
NCT05309018
Other Study ID Numbers:
  • 2021-07Obs-CHRMT
First Posted:
Apr 4, 2022
Last Update Posted:
Jul 14, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Régional Metz-Thionville
Advanced Practice Nurse
Acute Myeloid Leukemia,
Additional relevant MeSH terms:
Leukemia, Myeloid

Study Results

No Results Posted as of Jul 14, 2022